{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T11:21:12Z","timestamp":1789471272792,"version":"build-2803163510"},"reference-count":48,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","redjournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Radiation Oncology*Biology*Physics"],"published-print":{"date-parts":[[2023,2]]},"DOI":"10.1016\/j.ijrobp.2022.07.028","type":"journal-article","created":{"date-parts":[[2022,7,25]],"date-time":"2022-07-25T12:22:46Z","timestamp":1658751766000},"page":"347-355","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"title":["Effect of 3-Dimensional Interstitial High-Dose-Rate Brachytherapy With Regional Metastatic Lymph Node Intensity-Modulated Radiation Therapy in Locally Advanced Peripheral Non-Small Cell Lung Cancer: 5-Year Follow-up of a Phase 2 Clinical Trial"],"prefix":"10.1016","volume":"115","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3423-5065","authenticated-orcid":false,"given":"Li","family":"Xiang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pei-Rong","family":"Ren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hong-Xia","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hua","family":"Ye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hao-Wen","family":"Pang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qing-Lian","family":"Wen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jian-Wen","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li-Jia He","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chang-Ling","family":"Shang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bo","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sheng","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing-Bo","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ijrobp.2022.07.028_bib0001","doi-asserted-by":"crossref","first-page":"2181","DOI":"10.1200\/JCO.2009.26.2543","article-title":"Meta-analysis of concomitant versus sequential radiochemotherapy in locally advanced non-small-cell lung cancer","volume":"28","author":"Aup\u00e9rin","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ijrobp.2022.07.028_bib0002","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/j.annonc.2019.10.026","article-title":"Pan-Asian adapted ESMO Clinical Practice Guidelines for the management of patients with locally advanced unresectable non-small-cell lung cancer: A KSMO-ESMO initiative endorsed by CSCO, ISMPO, JSMO, MOS, SSO and TOS","volume":"31","author":"Park","year":"2020","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ijrobp.2022.07.028_bib0003","doi-asserted-by":"crossref","first-page":"2660","DOI":"10.1200\/JCO.2014.60.0130","article-title":"Multinational randomized phase III trial with or without consolidation chemotherapy using docetaxel and cisplatin after concurrent chemoradiation in inoperable stage III non-small-cell lung cancer: KCSG-LU05-04","volume":"33","author":"Ahn","year":"2015","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ijrobp.2022.07.028_bib0004","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1200\/JCO.19.01162","article-title":"Long-term results of NRG Oncology RTOG 0617: Standard- versus high-dose chemoradiotherapy with or without cetuximab for unresectable stage III non-small-cell lung cancer","volume":"38","author":"Bradley","year":"2020","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ijrobp.2022.07.028_bib0005","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/j.radonc.2019.03.009","article-title":"Individualized accelerated isotoxic concurrent chemo-radiotherapy for stage III non-small cell lung cancer: 5-year results of a prospective study","volume":"135","author":"De Ruysscher","year":"2019","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.ijrobp.2022.07.028_bib0006","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.jtho.2015.09.009","article-title":"The IASLC Lung Cancer Staging Project: Proposals for revision of the TNM stage groupings in the forthcoming (eighth) edition of the TNM classification for lung cancer","volume":"11","author":"Goldstraw","year":"2016","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.ijrobp.2022.07.028_bib0007","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1200\/JCO.21.01308","article-title":"Five-year survival outcomes from the PACIFIC Trial: Durvalumab after chemoradiotherapy in stage III non-small-cell lung cancer","volume":"40","author":"Spigel","year":"2022","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ijrobp.2022.07.028_bib0008","doi-asserted-by":"crossref","first-page":"1154","DOI":"10.1016\/j.ijrobp.2021.12.150","article-title":"Real-world safety and efficacy of consolidation durvalumab after chemoradiation therapy for stage III non-small cell lung cancer: A systematic review and meta-analysis","volume":"112","author":"Wang","year":"2022","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2022.07.028_bib0009","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/S1470-2045(21)00630-6","volume":"23","author":"Zhou","year":"2022","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ijrobp.2022.07.028_bib0010","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1016\/j.ijrobp.2019.08.034","article-title":"Patterns of disease progression with durvalumab in stage III non-small cell lung cancer (PACIFIC)","volume":"105","author":"Raben","year":"2019","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2022.07.028_bib0011","doi-asserted-by":"crossref","DOI":"10.1016\/j.critrevonc.2022.103684","article-title":"Open issues in the therapeutic management of unresectable stage III NSCLC in the immunotherapy era","volume":"174","author":"Catania","year":"2022","journal-title":"Crit Rev Oncol Hematol"},{"key":"10.1016\/j.ijrobp.2022.07.028_bib0012","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1097\/JTO.0b013e3182429682","article-title":"Defining local-regional control and its importance in locally advanced non-small cell lung carcinoma","volume":"7","author":"Machtay","year":"2012","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.ijrobp.2022.07.028_bib0013","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1016\/j.ijrobp.2010.09.004","article-title":"Higher biologically effective dose of radiotherapy is associated with improved outcomes for locally advanced non-small cell lung carcinoma treated with chemoradiation: An analysis of the Radiation Therapy Oncology Group","volume":"82","author":"Machtay","year":"2012","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2022.07.028_bib0014","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/j.ijrobp.2014.05.017","article-title":"30 Gy or 34 Gy? Comparing 2 single-fraction SBRT dose schedules for stage I medically inoperable non-small cell lung cancer","volume":"90","author":"Videtic","year":"2014","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2022.07.028_bib0015","first-page":"336","article-title":"Radiation dose effect in locally advanced non-small cell lung cancer","volume":"6","author":"Kong","year":"2014","journal-title":"J Thorac Dis"},{"key":"10.1016\/j.ijrobp.2022.07.028_bib0016","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1097\/COC.0b013e3180ca7cb1","article-title":"Stereotactic body radiation therapy: A comprehensive review","volume":"30","author":"Chang","year":"2007","journal-title":"Am J Clin Oncol"},{"key":"10.1016\/j.ijrobp.2022.07.028_bib0017","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/S1470-2045(14)71207-0","volume":"16","author":"Bradley","year":"2015","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ijrobp.2022.07.028_bib0018","doi-asserted-by":"crossref","first-page":"1358","DOI":"10.1001\/jamaoncol.2017.0982","article-title":"Effect of midtreatment PET\/CT-adapted radiation therapy with concurrent chemotherapy in patients with locally advanced non-small-cell lung cancer: A phase 2 clinical trial","volume":"3","author":"Kong","year":"2017","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.ijrobp.2022.07.028_bib0019","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1016\/j.jtho.2016.12.021","article-title":"Long-term results of a trial of concurrent chemotherapy and escalating doses of radiation for unresectable non-small cell lung cancer: NCCTG N0028 (Alliance)","volume":"12","author":"Schild","year":"2017","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.ijrobp.2022.07.028_bib0020","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/j.ijrobp.2014.09.033","article-title":"Is intermediate radiation dose escalation with concurrent chemotherapy for stage III non-small-cell lung cancer beneficial? A multi-institutional propensity score matched analysis","volume":"91","author":"Rodrigues","year":"2015","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2022.07.028_bib0021","article-title":"NRG-RTOG 1106\/ACRIN 6697: A phase IIR trial of standard versus adaptive (mid-treatment PET-based) chemoradiotherapy for stage III NSCLC-Results and comparison to NRG-RTOG 0617 (non-personalized RT dose escalation)","author":"Kong","year":"2021","journal-title":"ASCO"},{"key":"10.1016\/j.ijrobp.2022.07.028_bib0022","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1016\/j.ijrobp.2015.04.019","article-title":"Computed tomography-guided interstitial high-dose-rate brachytherapy in combination with regional positive lymph node intensity-modulated radiation therapy in locally advanced peripheral non-small cell lung cancer: A phase 1 clinical trial","volume":"92","author":"Xiang","year":"2015","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2022.07.028_bib0023","doi-asserted-by":"crossref","first-page":"4833","DOI":"10.1200\/JCO.2006.07.5937","article-title":"Excessive toxicity when treating central tumors in a phase II study of stereotactic body radiation therapy for medically inoperable early-stage lung cancer","volume":"24","author":"Timmerman","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ijrobp.2022.07.028_bib0024","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1016\/j.jvir.2010.01.011","article-title":"Quality improvement guidelines for percutaneous needle biopsy","volume":"21","author":"Gupta","year":"2010","journal-title":"J Vasc Interv Radiol"},{"key":"10.1016\/j.ijrobp.2022.07.028_bib0025","doi-asserted-by":"crossref","first-page":"1452","DOI":"10.1093\/jnci\/djr325","article-title":"Sequential vs. concurrent chemoradiation for stage III non-small cell lung cancer: Randomized phase III trial RTOG 9410","volume":"103","author":"Curran","year":"2011","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.ijrobp.2022.07.028_bib0026","doi-asserted-by":"crossref","DOI":"10.1001\/jamaoncol.2017.2032","article-title":"Proton beam radiotherapy and concurrent chemotherapy for unresectable stage III non-small cell lung cancer: Final results of a phase 2 study","volume":"3","author":"Chang","year":"2017","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.ijrobp.2022.07.028_bib0027","doi-asserted-by":"crossref","first-page":"1813","DOI":"10.1200\/JCO.2017.74.0720","article-title":"Bayesian adaptive randomization trial of passive scattering proton therapy and intensity-modulated photon radiotherapy for locally advanced non-small-cell lung cancer","volume":"36","author":"Liao","year":"2018","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ijrobp.2022.07.028_bib0028","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.1001\/jamaoncol.2018.1251","article-title":"Stereotactic body radiation therapy for operable early-stage lung cancer: Findings from the NRG Oncology RTOG 0618 trial","volume":"4","author":"Timmerman","year":"2018","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.ijrobp.2022.07.028_bib0029","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/j.ijrobp.2021.04.014","article-title":"Stereotactic body radiation therapy with a high maximum dose improves local control, cancer-specific death, and overall survival in peripheral early-stage non-small cell lung cancer","volume":"111","author":"Tateishi","year":"2021","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2022.07.028_bib0030","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1016\/j.ijrobp.2015.07.2260","article-title":"A randomized phase 2 study comparing 2 stereotactic body radiation therapy schedules for medically inoperable patients with stage I peripheral non-small cell lung cancer: NRG Oncology RTOG 0915 (NCCTG N0927)","volume":"93","author":"Videtic","year":"2015","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"15","key":"10.1016\/j.ijrobp.2022.07.028_bib0031","doi-asserted-by":"crossref","first-page":"e21047","DOI":"10.1200\/JCO.2020.38.15_suppl.e21047","article-title":"Phase II prospective trial of primary lung tumor stereotactic body radiation therapy (SBRT) followed by concurrent mediastinal chemoradiation and adjuvant immunotherapy for locally-advanced non-small cell lung cancer (NSCLC): Planned toxicity analysis","volume":"38","author":"Heinzerling","year":"2020","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ijrobp.2022.07.028_bib0032","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1016\/j.ijrobp.2016.08.032","article-title":"Stereotactic body radiation therapy boost after concurrent chemoradiation for locally advanced non-small cell lung cancer: A phase 1 dose escalation study","volume":"96","author":"Hepel","year":"2016","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2022.07.028_bib0033","doi-asserted-by":"crossref","first-page":"174","DOI":"10.4103\/0973-1482.82914","article-title":"Computerized tomography-guided percutaneous high-dose-rate interstitial brachytherapy for malignant lung lesions","volume":"7","author":"Sharma","year":"2011","journal-title":"J Cancer Res Ther"},{"key":"10.1016\/j.ijrobp.2022.07.028_bib0034","doi-asserted-by":"crossref","first-page":"2237","DOI":"10.1378\/chest.127.6.2237","article-title":"CT-guided interstitial single-fraction brachytherapy of lung tumors: Phase 1 results of a novel technique","volume":"127","author":"Ricke","year":"2005","journal-title":"Chest"},{"key":"10.1016\/j.ijrobp.2022.07.028_bib0035","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1007\/s00066-008-1718-5","article-title":"CT-guided interstitial brachytherapy of primary and secondary lung malignancies: Results of a prospective phase 2 trial","volume":"184","author":"Peters","year":"2008","journal-title":"Strahlenther Onkol"},{"key":"10.1016\/j.ijrobp.2022.07.028_bib0036","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1016\/j.radonc.2018.09.019","article-title":"The acute and late toxicity results of a randomized phase II dose-escalation trial in non-small cell lung cancer (PET-boost trial)","volume":"131","author":"van Diessen","year":"2019","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.ijrobp.2022.07.028_bib0037","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1016\/j.ijrobp.2017.10.042","volume":"100","author":"Jeter","year":"2018","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2022.07.028_bib0038","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1016\/j.radonc.2019.03.029","article-title":"Clinical outcomes after intensity-modulated proton therapy with concurrent chemotherapy for inoperable non-small cell lung cancer","volume":"136","author":"Elhammali","year":"2019","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.ijrobp.2022.07.028_bib0039","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.1200\/JCO.2016.71.6142","article-title":"Cardiac events after radiation therapy: Combined analysis of prospective multicenter trials for locally advanced non-small-cell lung cancer","volume":"35","author":"Dess","year":"2017","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ijrobp.2022.07.028_bib0040","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1016\/j.radonc.2016.01.007","article-title":"Acute esophagitis for patients with local-regional advanced non small cell lung cancer treated with concurrent chemoradiotherapy","volume":"118","author":"Pan","year":"2016","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.ijrobp.2022.07.028_bib0041","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/S0167-8140(97)00081-9","article-title":"Volume and dose parameters for survival of non-small cell lung cancer patients","volume":"44","author":"Martel","year":"1997","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.ijrobp.2022.07.028_bib0042","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1001\/jamaoncol.2015.3969","article-title":"Quality of life analysis of a radiation dose-escalation study of patients with non-small-cell lung cancer: A secondary analysis of the Radiation Therapy Oncology Group 0617 randomized clinical trial","volume":"2","author":"Movsas","year":"2016","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.ijrobp.2022.07.028_bib0043","doi-asserted-by":"crossref","first-page":"2946","DOI":"10.1200\/JCO.2005.05.153","article-title":"Clinically meaningful improvement in symptoms and quality of life for patients with non-small-cell lung cancer receiving gefitinib in a randomized controlled trial","volume":"23","author":"Cella","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ijrobp.2022.07.028_bib0044","doi-asserted-by":"crossref","DOI":"10.1259\/bjr.20190378","article-title":"Proton therapy for locally advanced non-small cell lung cancer","volume":"93","author":"Gjyshi","year":"2020","journal-title":"Br J Radiol"},{"key":"10.1016\/j.ijrobp.2022.07.028_bib0045","doi-asserted-by":"crossref","first-page":"1359","DOI":"10.1016\/j.ijrobp.2020.11.035","article-title":"Concurrent chemo-proton therapy using adaptive planning for unresectable stage 3 non-small cell lung cancer: A phase 2 study","volume":"109","author":"Iwata","year":"2021","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2022.07.028_bib0046","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2021.1959979","article-title":"Durvalumab after concurrent chemotherapy and high-dose radiotherapy for locally advanced non-small cell lung cancer","volume":"10","author":"Landman","year":"2021","journal-title":"Oncoimmunology"},{"key":"10.1016\/j.ijrobp.2022.07.028_bib0047","doi-asserted-by":"crossref","first-page":"2342","DOI":"10.1056\/NEJMoa1809697","article-title":"Overall survival with durvalumab after chemoradiotherapy in stage III NSCLC","volume":"379","author":"Antonia","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ijrobp.2022.07.028_bib0048","doi-asserted-by":"crossref","first-page":"2097","DOI":"10.21037\/tlcr-20-511","article-title":"Radiotherapy for unresectable locally advanced non-small cell lung cancer: A narrative review of the current landscape and future prospects in the era of immunotherapy","volume":"9","author":"Guo","year":"2020","journal-title":"Transl Lung Cancer Res"}],"container-title":["International Journal of Radiation Oncology*Biology*Physics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0360301622007520?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0360301622007520?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,6]],"date-time":"2025-10-06T10:05:07Z","timestamp":1759745107000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0360301622007520"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,2]]},"references-count":48,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2023,2]]}},"alternative-id":["S0360301622007520"],"URL":"https:\/\/doi.org\/10.1016\/j.ijrobp.2022.07.028","relation":{},"ISSN":["0360-3016"],"issn-type":[{"value":"0360-3016","type":"print"}],"subject":[],"published":{"date-parts":[[2023,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Effect of 3-Dimensional Interstitial High-Dose-Rate Brachytherapy With Regional Metastatic Lymph Node Intensity-Modulated Radiation Therapy in Locally Advanced Peripheral Non-Small Cell Lung Cancer: 5-Year Follow-up of a Phase 2 Clinical Trial","name":"articletitle","label":"Article Title"},{"value":"International Journal of Radiation Oncology*Biology*Physics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijrobp.2022.07.028","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}